Clinical trials: Sexual Arousal Disorder
Sexual Dysfunction, Physiological
Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women
This randomized, double-blind, placebo-controlled clinical trial investigated the effect of once daily oral administration of 20 mg estetrol monohydrate tablet for 12 weeks in postmenopausal women who experienced sexual arousal…
- Trial name
- NCT06308614
- Testing
- Estetrol
- Where
- 24 sites in United States
- Volunteers
- 82 people
- Sponsor
- Estetra
Sexual Dysfunction, Physiological
Vaginal Heat Wash-out (HWO) in 4 Groups of Women (Pre- and Postmenopausal With and Without Female Sexual Arousal Disorder (FSAD)).
The Pfizer developed Heat Wash-Out (HWO) system is a software controlled electromechanical system designed to measure vaginal wall blood flow. A small vaginal probe is attached to a control unit.
- Trial name
- FSAD HWO VBF (NCT00443248)
- Testing
- Vaginal Heat Wash-Out Device
- Where
- 2 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pfizer
Sexual Dysfunction, Physiological
Topical Alprostadil for Female Sexual Arousal Disorder
Approximately 300 patients with female sexual arousal disorder who meet eligibility criteria will be enrolled and randomized to receive either active drug or matching placebo.
- Trial name
- NCT00324948
- Testing
- Topical alprostadil (PGE-1)
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- VIVUS LLC
Sexual Arousal Disorder
Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder
This is a Phase 2, single center, single-dose, double-blind, placebo-controlled, 2-way crossover study to evaluate the safety and efficacy of SST-6007 in women with FSAD.
- Trial name
- NCT02570282
- Testing
- SST-6007
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Strategic Science & Technologies, LLC
Sexual Dysfunction, Physiological
The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.
CP-866,087 is a non-hormonal compound, acting on the central nervous system, which has been shown in animal models to restore sexual function.
- Trial name
- NCT00482664
- Testing
- CP-866,087
- Where
- 12 sites in Australia, Denmark and 3 more
- Volunteers
- 84 people
- Sponsor
- Pfizer
Female Sexual Arousal Disorder, Female Sexual Dysfunction (FSD)
Evaluation of the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Women With Sexual Arousal Disorder
Evaluation of the efficacy in increasing sexual arousal, safety and tolerability of BZ371A in gel form applied to women with sexual arousal disorder
- Trial name
- NCT06651541
- Testing
- BZ371A (0.5 ml), BZ371A (1.0 ml)
- Where
- Brazil
- Volunteers
- 174 people
- Sponsor
- Biozeus Biopharmaceutical S.A.
Sexual Dysfunction, Sexual Arousal Disorder
Study to Investigate the Effect of AB-101 in Breast Cancer Survivors
The purpose of this research study is to investigate the possibility that a topical drug could restore nipple sensitivity and improve sexual quality of life in breast cancer survivors.
- Conditions
- Sexual Dysfunction, Sexual Arousal Disorder, Sexual Dysfunction, Physiological, Breast Cancer
- Trial name
- NCT03592121
- Testing
- AB-101
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Applied Biology, Inc.
Female Sexual Dysfunction
Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety and Efficacy
This study is evaluating the safety and efficacy of the Geneveve Treatment for women experiencing diminished sexual function following vaginal childbirth.
- Trial name
- VIVEVE II (NCT03479229)
- Testing
- Geneveve Treatment
- Where
- 21 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Viveve Inc.
Sexual Dysfunctions, Psychological, Sexual Arousal Disorder
An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder
The purpose of this study is to evaluate the safety and toleration of oral sildenafil administered as required by women with Female Sexual Arousal Disorder (FSAD) who successfully complete one of the following Pfizer-sponsored…
- Trial name
- NCT00746967
- Testing
- sildenafil
- Where
- 82 sites in United States
- Volunteers
- 267 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Female Sexual Arousal Disorder
Clinical Trial to Investigate the Effectiveness of a Dietary Supplement in Increasing Libido and Sexual Function in Postmenopausal Women.
This clinical Trial will assess the effects of a dietary supplement based on Tribulus terrestris on the libido and sexual function in postmenopausal women, by doing a follow up of the FSFI scale and different variables during 3…
- Trial name
- NCT03820453
- Testing
- Tribulus Terrestris
- Where
- 4 sites in Spain
- Volunteers
- 110 people
- Sponsor
- Kern Pharma, S.L.
Female Sexual Arousal Disorder, Female Sexual Dysfunction
Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder
To determine the efficacy in increasing sexual arousal, safety and tolerability of BZ371A in gel form applied to women with sexual arousal disorder.
- Trial name
- NCT06116045
- Testing
- BZ371A 7.5 mg (1.5 ml), BZ371A 5.0 mg (1.0 ml), BZ371A 2.5 mg (0.5 ml)
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Biozeus Biopharmaceutical S.A.
Female Sexual Arousal Disorder
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder
This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil…
- Trial name
- RESPOND (NCT04948151)
- Testing
- Sildenafil
- Where
- 51 sites in United States
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Strategic Science & Technologies, LLC
Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal…
- Trial name
- NCT01382719
- Testing
- bremelanotide
- Where
- 68 sites in United States, Canada
- Volunteers
- 612 people
- Sponsor
- Palatin Technologies, Inc
Hypoactive Sexual Desire Disorder
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
The purpose of this study is to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder(with or without Decreased Arousal).
- Trial name
- NCT04943068
- Testing
- Bremelanotide
- Where
- South Korea
- Volunteers
- 193 people
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined), Sexual Interest/Arousal Disorder (DSM-5 Defined)
Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety
The purpose of this study is to investigate whether Lorexys is effective and safe to treat premenopausal women who have lost their sexual desire to a distressing degree.
- Trial name
- PURPLE (NCT01857596)
- Testing
- bupropion, Lorexys low-dose, Lorexys moderate-dose
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- S1 Biopharma, Inc.
Sexual Arousal Disorder
Using Thermography to Assess the Affects of Sildenafil Cream, 3.6%
The goal of this clinical trial is to compare thermography images in normal healthy premenopausal women after the application of Sildenafil Cream, 3.6%, L-arginine cream, and placebo cream.
- Trial name
- NCT05765487
- Testing
- Sildenafil, Vehicle
- Where
- Canada
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Daré Bioscience, Inc.
Female Sexual Interest/Arousal Disorder
Study to Evaluate the Effectiveness and Safety of Libicare® in Women With Low Arousal and Sexual Desire Levels
The purpose of this study is to evaluate the effectiveness of Libicare® in the sexual desire and arousal at 12 weeks in peri or postmenopausal women aged between 40 and 60 years old with low sexual desire and arousal compared…
- Trial name
- VITAL (NCT04188600)
- Testing
- Libicare, active control
- Where
- Spain
- Sponsor
- Procare Health Iberia S.L.
Sexual Arousal Disorder
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.
- Trial name
- NCT00425256
- Testing
- Bremelanotide
- Where
- 20 sites in United States
- Sponsor
- Palatin Technologies, Inc
Sexual Dysfunction, Psychological
Zestra in Women With Mixed Sexual Dysfunction
The objective of this study is to evaluate the clinical efficacy and safety of Zestra(TM) in women with acquired mixed desire/interest/arousal/orgasm disorders under conditions of home usage.
- Trial name
- NCT00118495
- Testing
- Non-prescription Zestra(TM): patented formulation
- Where
- 13 sites in United States
- Volunteers
- 200 people
- Sponsor
- QualiLife Pharmaceuticals
Sexual Dysfunction
Efficacy of Tibolone Versus Transdermal E2/NETA on Sexual Function in Naturally Postmenopausal Women (P06089)
Tibolone has been registered for treatment of menopausal symptoms. It is, however, not known what the effects are of tibolone in postmenopausal women diagnosed with sexual dysfunction.
- Trial name
- NCT00413764
- Testing
- tibolone, estradiol-norethisterone
- Volunteers
- 358 people
- Sponsor
- Organon and Co